Skip to main content
Log in

Arsenic trioxide ameliorates murine colon inflammation through inflammatory cell enzymatic modulation

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Arsenic trioxide (As2O3) is a trending subject in recent therapy approaches despite its described toxicity. In this work, we have investigated the use of arsenic trioxide in a murine model of chemically induced inflammatory bowel disease “colitis.” Male mice were randomly separated into four different groups. Controls received vehicle, arsenic group had a daily injection of As2O3 (2.5 mg/kg, i.p.) for 2 days. Colitis was induced through intra-rectal instillation of 4% (v/v) solution of acetic acid in the second day. The treatment group (As2O3 + acetic acid) received the same treatment as the two previous groups. Twenty-four hours after colitis challenge, animals were sacrificed and organs (colons, livers, and kidneys) were taken for analysis. Disease-related macroscopic and microscopic symptoms, as well as histologic observations, showed a high index in the colitis group, which was greatly reduced by the As2O3 pretreatment. Similarly, colon length was reduced during colon inflammation, which was prevented in the presence of As2O3. Inflammatory cells and oxidative stress markers significantly increased during inflammation accompanied by a considerable reduction of antioxidants. As2O3 treatment managed to reverse these observations to normal levels. Mitochondrial implication was observed through mPTP opening phenomena and semi-quantitative cell death estimation. Low-dose As2O3 use as a mean of preventing the acute phase of colitis can be seen as an interesting approach which counts as a great addition to IBD available treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

Download references

Acknowledgments

This work was supported by the DGRSDT (Direction Générale de la Recherche Scientifique et du Développement Technologique), Algiers, Algeria (PNR project, ATRSS/PNR 08/N°305).

Author information

Authors and Affiliations

Authors

Contributions

HM, BMAB, AB, and BD conceived and designed the research plan. HM, BMAB, and MF conducted experiments. HM, BMAB, and MF analyzed the data. HM wrote the manuscript. AB and BD supervised the work. All authors read and approved the manuscript.

Corresponding author

Correspondence to Hichem Moulahoum.

Ethics declarations

All experiments were performed according to the “Ethics Committee for handling laboratory animals” guidelines at the “University of Sciences and Technology Houari Boumediene, Algiers, Algeria.”

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moulahoum, H., Boumaza, B.M.A., Ferrat, M. et al. Arsenic trioxide ameliorates murine colon inflammation through inflammatory cell enzymatic modulation. Naunyn-Schmiedeberg's Arch Pharmacol 392, 259–270 (2019). https://doi.org/10.1007/s00210-018-1578-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-018-1578-1

Keywords

Navigation